Keywords: Parkinsons, fipamezole, Santhera, Juvantia
Santhera buys Juvantia to get rights to Parkinson’s drug fipamezole
Article | 17 August 2009
Swiss biotechnology firm Santhera Pharmaceuticals has entered into an agreement to gain rights to JP-1730/fipamezole from Finland-based Oy Juvantia ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
